508 related articles for article (PubMed ID: 32680477)
1. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.
Finger RP; Daien V; Eldem BM; Talks JS; Korobelnik JF; Mitchell P; Sakamoto T; Wong TY; Pantiri K; Carrasco J
BMC Ophthalmol; 2020 Jul; 20(1):294. PubMed ID: 32680477
[TBL] [Abstract][Full Text] [Related]
2. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
4. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Holekamp N; Gentile B; Giocanti-Aurégan A; García-Layana A; Peto T; Viola F; Kertes PJ; Mirt M; Kotecha A; Lambert J; Lewis HB; Chi GC
Ophthalmic Res; 2024; 67(1):311-321. PubMed ID: 38679018
[TBL] [Abstract][Full Text] [Related]
5. The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden.
Gale RP; Finger RP; Eldem B; Aslam T; Barratt J; Daien V; Kodjikian L; Loewenstein A; Okada M; Wong TY; Sylvanowicz M; Rodríguez FJ
Acta Ophthalmol; 2023 Feb; 101(1):e26-e42. PubMed ID: 35790079
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
[TBL] [Abstract][Full Text] [Related]
7. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration.
Finger RP; Guymer RH; Gillies MC; Keeffe JE
Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613
[TBL] [Abstract][Full Text] [Related]
8. The First-Year Variation in Central Retinal Thickness Predicts Legal Blindness in Patients with Neovascular Age-Related Macular Degeneration.
Guo Y; Wu J; Zheng X; Yin C; Wu Z
Ophthalmic Res; 2023; 66(1):406-412. PubMed ID: 36436501
[TBL] [Abstract][Full Text] [Related]
9. Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry.
Nguyen V; Barthelmes D; Gillies MC
Clin Exp Ophthalmol; 2021 Sep; 49(7):652-663. PubMed ID: 34013534
[TBL] [Abstract][Full Text] [Related]
10. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
11. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
12. Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview.
Balatsoukas DD; Tsaousis KT; Boboridis KG; Konstas AG; Topouzis F
Adv Ther; 2022 Jan; 39(1):5-32. PubMed ID: 34724151
[TBL] [Abstract][Full Text] [Related]
13. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
14. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review.
Senra H; Ali Z; Balaskas K; Aslam T
Graefes Arch Clin Exp Ophthalmol; 2016 Oct; 254(10):1873-1880. PubMed ID: 27262729
[TBL] [Abstract][Full Text] [Related]
15. A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration.
van der Reis MI; Elshout M; Berendschot TTJM; de Jong-Hesse Y; Webers CAB; Schouten JSAG
BMC Ophthalmol; 2020 Jan; 20(1):21. PubMed ID: 31918701
[TBL] [Abstract][Full Text] [Related]
16. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Obeid A; Gao X; Ali FS; Aderman CM; Shahlaee A; Adam MK; Kasi SK; Hyman L; Ho AC; Hsu J
JAMA Ophthalmol; 2018 Nov; 136(11):1251-1259. PubMed ID: 30352121
[TBL] [Abstract][Full Text] [Related]
17. Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion.
Sadda SR; Guymer R; Monés JM; Tufail A; Jaffe GJ
Ophthalmology; 2020 May; 127(5):648-659. PubMed ID: 32081493
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
19. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
Fauser S; Viebahn U; Muether PS
Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
[TBL] [Abstract][Full Text] [Related]
20. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
